A carregar...
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study
BACKGROUND: RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall surv...
Na minha lista:
Main Authors: | , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Oxford University Press
2013
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3688018/ https://ncbi.nlm.nih.gov/pubmed/23788270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not049 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|